502 related articles for article (PubMed ID: 36848790)
1. Highlights into historical and current immune interventions for cancer.
Cole K; Al-Kadhimi Z; Talmadge JE
Int Immunopharmacol; 2023 Apr; 117():109882. PubMed ID: 36848790
[TBL] [Abstract][Full Text] [Related]
2. A retrospective study of immunotherapy using the cell wall skeleton of Mycobacterium bovis Bacillus Calmette-Guérin (BCG-CWS) for cervical cancer.
Shibata T; Takata E; Sakamoto J; Shioya A; Yamada S; Takakura M; Sasagawa T
Medicine (Baltimore); 2022 Dec; 101(52):e32481. PubMed ID: 36595982
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy for the Treatment of Urothelial Carcinoma.
Donin NM; Lenis AT; Holden S; Drakaki A; Pantuck A; Belldegrun A; Chamie K
J Urol; 2017 Jan; 197(1):14-22. PubMed ID: 27460757
[TBL] [Abstract][Full Text] [Related]
4. Bacillus Calmette-Guérin strain differences as the basis for immunotherapies against bladder cancer.
Miyazaki J; Onozawa M; Takaoka E; Yano I
Int J Urol; 2018 May; 25(5):405-413. PubMed ID: 29506322
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guérin (BCG) hsp65 and HPV16 E7.
Chu NR; Wu HB; Wu T; Boux LJ; Siegel MI; Mizzen LA
Clin Exp Immunol; 2000 Aug; 121(2):216-25. PubMed ID: 10931134
[TBL] [Abstract][Full Text] [Related]
6. CREST: phase III study of sasanlimab and Bacillus Calmette-Guérin for patients with Bacillus Calmette-Guérin-naïve high-risk non-muscle-invasive bladder cancer.
Steinberg GD; Shore ND; Redorta JP; Galsky MD; Bedke J; Ku JH; Kretkowski M; Hu H; Penkov K; Vermette JJ; Tarazi JC; Randall AE; Pierce KJ; Saltzstein D; Powles TB
Future Oncol; 2024 May; 20(14):891-901. PubMed ID: 38189180
[TBL] [Abstract][Full Text] [Related]
7. Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients.
Derré L; Cesson V; Lucca I; Cerantola Y; Valerio M; Fritschi U; Vlamopoulos Y; Burruni R; Legris AS; Dartiguenave F; Gharbi D; Martin V; Vaucher L; Speiser DE; Romero P; Jichlinski P; Nardelli-Haefliger D
Clin Cancer Res; 2017 Feb; 23(3):717-725. PubMed ID: 27521445
[TBL] [Abstract][Full Text] [Related]
8. Emerging Immunotherapy Options for bacillus Calmette-Guérin Unresponsive Nonmuscle Invasive Bladder Cancer.
Meng MV; Gschwend JE; Shore N; Grossfeld GD; Mostafid H; Black PC
J Urol; 2019 Dec; 202(6):1111-1119. PubMed ID: 31042108
[TBL] [Abstract][Full Text] [Related]
9. Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intralesional
Da Gama Duarte J; Parakh S; Andrews MC; Woods K; Pasam A; Tutuka C; Ostrouska S; Blackburn JM; Behren A; Cebon J
Front Immunol; 2018; 9():411. PubMed ID: 29552014
[TBL] [Abstract][Full Text] [Related]
10. Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches.
Song D; Powles T; Shi L; Zhang L; Ingersoll MA; Lu YJ
J Pathol; 2019 Oct; 249(2):151-165. PubMed ID: 31102277
[TBL] [Abstract][Full Text] [Related]
11. A Phase 1/2 Single-arm Clinical Trial of Recombinant Bacillus Calmette-Guérin (BCG) VPM1002BC Immunotherapy in Non-muscle-invasive Bladder Cancer Recurrence After Conventional BCG Therapy: SAKK 06/14.
Rentsch CA; Thalmann GN; Lucca I; Kwiatkowski M; Wirth GJ; Strebel RT; Engeler D; Pedrazzini A; Hüttenbrink C; Schultze-Seemann W; Torpai R; Bubendorf L; Wicki A; Roth B; Bosshard P; Püschel H; Boll DT; Hefermehl L; Roghmann F; Gierth M; Ribi K; Schäfer S; Hayoz S
Eur Urol Oncol; 2022 Apr; 5(2):195-202. PubMed ID: 35012889
[TBL] [Abstract][Full Text] [Related]
12. Bacillus Calmette-Guérin (BCG) infection following intravesical BCG administration as adjunctive therapy for bladder cancer: incidence, risk factors, and outcome in a single-institution series and review of the literature.
Pérez-Jacoiste Asín MA; Fernández-Ruiz M; López-Medrano F; Lumbreras C; Tejido Á; San Juan R; Arrebola-Pajares A; Lizasoain M; Prieto S; Aguado JM
Medicine (Baltimore); 2014 Oct; 93(17):236-254. PubMed ID: 25398060
[TBL] [Abstract][Full Text] [Related]
13. Systemic therapy issues: Immunotherapy in nonmetastatic urothelial cancer.
Nadal R; Apolo AB; Girardi DM; Hahn NM; Bellmunt J
Urol Oncol; 2023 Jan; 41(1):27-34. PubMed ID: 34756410
[TBL] [Abstract][Full Text] [Related]
14. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder.
Lamm DL; Blumenstein BA; Crawford ED; Montie JE; Scardino P; Grossman HB; Stanisic TH; Smith JA; Sullivan J; Sarosdy MF
N Engl J Med; 1991 Oct; 325(17):1205-9. PubMed ID: 1922207
[TBL] [Abstract][Full Text] [Related]
15. Bacillus Calmette-Guérin immunotherapy for genitourinary cancer.
Gandhi NM; Morales A; Lamm DL
BJU Int; 2013 Aug; 112(3):288-97. PubMed ID: 23517232
[TBL] [Abstract][Full Text] [Related]
16. Antitumor Efficacy of Bacillus Calmette-Guerin Loaded Cationic Nanoparticles for Intravesical Immunotherapy of Bladder Tumor Induced Rat Model.
Erdoğar N; Iskit AB; Eroğlu H; Sargon MF; Mungan NA; Bilensoy E
J Nanosci Nanotechnol; 2015 Dec; 15(12):10156-64. PubMed ID: 26682462
[TBL] [Abstract][Full Text] [Related]
17. Predicting Response to Intravesical Bacillus Calmette-Guérin Immunotherapy: Are We There Yet? A Systematic Review.
Kamat AM; Li R; O'Donnell MA; Black PC; Roupret M; Catto JW; Comperat E; Ingersoll MA; Witjes WP; McConkey DJ; Witjes JA
Eur Urol; 2018 May; 73(5):738-748. PubMed ID: 29055653
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy in Bacillus Calmette-Guerin (BCG) unresponsive nonmuscle invasive bladder cancer.
Hugar LA; Gilbert SM; Sexton WJ; Kamat AM; Li R
Curr Opin Urol; 2021 Mar; 31(2):160-169. PubMed ID: 33394766
[TBL] [Abstract][Full Text] [Related]
19. Preoperative sarcopenia and systemic immune-inflammation index can predict response to intravesical Bacillus Calmette-Guerin instillation in patients with non-muscle invasive bladder cancer.
Liu P; Chen S; Gao X; Liang H; Sun D; Shi B; Zhang Q; Guo H
Front Immunol; 2022; 13():1032907. PubMed ID: 36225922
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
